- Home
- LMB vs COLL Comparison
LMB vs COLL Comparison
Compare LMB & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LMB
- COLL
- Stock Information
- Founded
- LMB 1901
- COLL 2002
- Country
- LMB United States
- COLL United States
- Employees
- LMB N/A
- COLL N/A
- Industry
- LMB Engineering & Construction
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- LMB Consumer Discretionary
- COLL Health Care
- Exchange
- LMB Nasdaq
- COLL Nasdaq
- Market Cap
- LMB 1.1B
- COLL 1.0B
- IPO Year
- LMB 2014
- COLL 2015
- Fundamental
- Price
- LMB $100.65
- COLL $30.93
- Analyst Decision
- LMB Strong Buy
- COLL Strong Buy
- Analyst Count
- LMB 3
- COLL 5
- Target Price
- LMB $115.00
- COLL $43.60
- AVG Volume (30 Days)
- LMB 216.5K
- COLL 441.9K
- Earning Date
- LMB 03-12-2025
- COLL 02-20-2025
- Dividend Yield
- LMB N/A
- COLL N/A
- EPS Growth
- LMB 29.01
- COLL 757.11
- EPS
- LMB 2.18
- COLL 2.16
- Revenue
- LMB $517,822,000.00
- COLL $599,245,000.00
- Revenue This Year
- LMB $2.59
- COLL $13.25
- Revenue Next Year
- LMB $12.46
- COLL $18.14
- P/E Ratio
- LMB $44.29
- COLL $14.24
- Revenue Growth
- LMB 0.13
- COLL 9.62
- 52 Week Low
- LMB $38.03
- COLL $28.39
- 52 Week High
- LMB $107.00
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- LMB 44.58
- COLL 45.90
- Support Level
- LMB $86.19
- COLL $32.28
- Resistance Level
- LMB $101.65
- COLL $33.45
- Average True Range (ATR)
- LMB 6.65
- COLL 1.07
- MACD
- LMB -0.82
- COLL -0.16
- Stochastic Oscillator
- LMB 19.74
- COLL 2.05
About LMB Limbach Holdings Inc.
Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.